Baseline lymphocyte and cholinesterase levels may be the predictors of chronic herbal drug–induced liver injury

Objective: To investigate the factors influencing the chronicity of drug-induced liver injury (DILI) caused by Chinese herbal medicine. Methods: Patients with DILI diagnosed by using the RUCAM score were enrolled retrospectively. The subjects were patients with DILI induced by taking Chinese herbal medicine and were followed up for 48 weeks. These patients were divided into a cure group and a chronic group. The biochemical indicators were monitored at baseline and every 3 months. Logistic regression was used to analyze the risk factors of DILI chronicity. The ROC (receiver operator characteristic) curve was used to analyze the diagnostic efficiency of each factor. Results: A total of 420 patients with DILI were enrolled; 122 of them were caused by Chinese herbal medicine, 70.5% (86/122) of them were female, chronic group 31.2% (39/122), and cure group 68.0% (83/122); cholinesterase (ChE) in the chronic group was lower than that in the cure group (5467.10 ± 2010.40 U/L vs. 6248.52 ± 1901.78 U/L, p = 0.04, t = 2.078). There was no significant difference in the age between cured patients and chronic patients (p = 0.156, Z = −1.417). There was no significant difference between the prognosis of different genders (p = 0.521, Z = −0.639). The logistic regression analysis showed that baseline lymphocyte (OR = 0.429, 95%CI = 0.205–0.898, p = 0.025) and cholinesterase (OR = 0.088, 95%CI = 0.008–0.994, p = 0.049) were independent risk factors of drug-induced chronicity. Conclusion: Baseline lymphocyte and cholinesterase may be the predictive factors for the chronicity of Chinese herbal medicine–induced liver injury.

[1]  William M. Lee,et al.  Acute liver failure , 2019, The Lancet.

[2]  P. Watkins,et al.  Drug-induced liver injury , 2019, Nature Reviews Disease Primers.

[3]  Ming Yan,et al.  Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. , 2019, Gastroenterology.

[4]  R. Andrade,et al.  Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice , 2019, Seminars in Liver Disease.

[5]  K. Lam,et al.  Literature Review of Traditional Chinese Medicine Herbs–Induced Liver Injury From an Oncological Perspective With RUCAM , 2019, Integrative cancer therapies.

[6]  R. Fontana,et al.  The diagnosis and management of idiosyncratic drug‐induced liver injury , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[7]  R. Andrade,et al.  Chronic liver injury induced by drugs and toxins , 2018, Journal of digestive diseases.

[8]  A. Soliman,et al.  Assessment of serum level cholinesterase as a biomarker of liver cirrhosis in Egyptian cirrhotic patients , 2017 .

[9]  W. Cong,et al.  CSH guidelines for the diagnosis and treatment of drug-induced liver injury , 2017, Hepatology International.

[10]  N. Chalasani,et al.  Chronic liver injury induced by drugs: a systematic review , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  William M. Lee,et al.  Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. , 2015, Gastroenterology.

[12]  William M. Lee,et al.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. , 2014, Gastroenterology.

[13]  H. Bonkovsky,et al.  Herbal and dietary supplement hepatotoxicity , 2014, Clinical liver disease.

[14]  M. Pirmohamed,et al.  Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. , 2011, The Journal of allergy and clinical immunology.

[15]  M. Molokhia,et al.  Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.

[16]  R. Fontana,et al.  Mechanisms of drug-induced liver injury: from bedside to bench , 2011, Nature Reviews Gastroenterology &Hepatology.

[17]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[18]  R. Andrade,et al.  Outcome of acute idiosyncratic drug‐induced liver injury: Long‐term follow‐up in a hepatotoxicity registry , 2006, Hepatology.

[19]  O. O. Ogunkeye,et al.  Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests. , 2006, Pathophysiology : the official journal of the International Society for Pathophysiology.

[20]  W. Pichler,et al.  Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.

[21]  R. Victorino,et al.  Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury , 1997, Gut.

[22]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[23]  D. Harnois.  Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .

[24]  R. Fontana,et al.  Drug-Induced Liver Injury Network (DILIN) Prospective Study , 2009, Drug safety.

[25]  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.